Qiagen to acquire "pre-molecular" diags firm Cellestis for $354m
This article was originally published in Clinica
Executive Summary
Dutch molecular diagnostics specialist Qiagen is to further diversify its offerings with the proposed acquisition of Cellestis, an Australian company that specialises in a novel "pre-molecular" testing technology.